These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31822200)

  • 61. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
    J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Retrospective Study of Double-hit Lymphomas in Elderly Patients (Aged > 70 Years): Overall Outcomes.
    Hancock C; Knouse P; Almanaseer I; Bitran J
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):280-285. PubMed ID: 29500147
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
    Khaled HM; Zekri ZK; Mokhtar N; Ali NM; Darwish T; Elattar I; Gaafar R; Moawad MS
    Ann Oncol; 1999 Dec; 10(12):1489-92. PubMed ID: 10643541
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.
    Chihara D; Westin JR; Oki Y; Ahmed MA; Do B; Fayad LE; Hagemeister FB; Romaguera JE; Fanale MA; Lee HJ; Turturro F; Samaniego F; Neelapu SS; Rodriguez MA; Fowler NH; Wang M; Davis RE; Nastoupil LJ
    Cancer; 2016 Oct; 122(20):3145-3151. PubMed ID: 27351173
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
    Dix S; Cord M; Howard S; Coon J; Belt R; Geller R
    Bone Marrow Transplant; 1999 Sep; 24(5):561-6. PubMed ID: 10482943
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
    Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
    Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
    [TBL] [Abstract][Full Text] [Related]  

  • 70. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessment of Outpatient and Inpatient Antibiotic Treatment Patterns and Health Care Costs of Patients with Complicated Urinary Tract Infections.
    Turner RM; Wu B; Lawrence K; Hackett J; Karve S; Tunceli O
    Clin Ther; 2015 Sep; 37(9):2037-47. PubMed ID: 26212569
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aggressive lymphoma: improving treatment outcome with rituximab.
    Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
    Moskowitz CH; Bertino JR; Glassman JR; Hedrick EE; Hunte S; Coady-Lyons N; Agus DB; Goy A; Jurcic J; Noy A; O'Brien J; Portlock CS; Straus DS; Childs B; Frank R; Yahalom J; Filippa D; Louie D; Nimer SD; Zelenetz AD
    J Clin Oncol; 1999 Dec; 17(12):3776-85. PubMed ID: 10577849
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
    Wilson WH; Bates SE; Fojo A; Bryant G; Zhan Z; Regis J; Wittes RE; Jaffe ES; Steinberg SM; Herdt J
    J Clin Oncol; 1995 Aug; 13(8):1995-2004. PubMed ID: 7636540
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.
    Elting LS; Lu C; Escalante CP; Giordano SH; Trent JC; Cooksley C; Avritscher EB; Shih YC; Ensor J; Bekele BN; Gralla RJ; Talcott JA; Rolston K
    J Clin Oncol; 2008 Feb; 26(4):606-11. PubMed ID: 18235119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.